US Bancorp
ARLZ

US Bancorp’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

US Bancorp’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14,307
Closed -$31K – 3734
2017
Q1 		$31K Buy
14,307
+1,264
+10% +$4.75K ﹤0.01% 2705
2016
Q4 		$58K Buy
13,043
+633
+5% +$3K ﹤0.01% 2370
2016
Q3 		$60K Buy
12,410
+3,834
+45% +$17.5K ﹤0.01% 2354
2016
Q2 		$28K Hold
8,576
– – ﹤0.01% 2673
2016
Q1 		$30K Buy
+8,576
New +$44.2K ﹤0.01% 2619

Other funds holding ARLZ

PCM
PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return

US Bancorp's ARLZ Position: Q2 2017 in Review

US Bancorp sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q2 2017, closing a stake of 14,307 shares — an estimated $31K sold.

US Bancorp first reported a position in ARLZ in Q1 2016 and held it in 5 quarters. The position peaked at $60K in Q3 2016. 72 funds tracked by Wall St. Rank hold ARLZ as of Q2 2017.

  • US Bancorp reported no remaining Aralez Pharmaceuticals Inc. position as of Q2 2017 after selling out during the quarter.
  • US Bancorp sold 14,307 Aralez Pharmaceuticals Inc. shares in Q2 2017, an estimated $31K.
  • US Bancorp first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 5 quarters.
  • US Bancorp's Aralez Pharmaceuticals Inc. position peaked at $60K in Q3 2016.
  • 72 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q2 2017.

Based on US Bancorp's 13F filing for Q2 2017, filed 20 Jul 2017.